Capsule Summary Slidesets

Share

Program Content

Activities

  • GSK3640254 Phase IIa Trial
    Novel, Next-Generation HIV-1 Maturation Inhibitor GSK3640254 Demonstrates Dose-Dependent Antiviral Response in Treatment-Naive Patients With HIV Infection
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 10, 2021

    Expires: March 09, 2022

  • COVID-19 Racial Disparities in PWH
    Racial Differences in COVID-19 Infection Rates Among PWH in the United States
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 12, 2021

    Expires: March 11, 2022

  • HPTN 083: Incident Infections
    HPTN 083: Incident Infections and Emergent Resistance in MSM and TGW Receiving Cabotegravir Long-Acting PrEP
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 10, 2021

    Expires: March 09, 2022

  • COVID-19 in Pregnancy
    COVID-19, But not HIV Infection, Is Associated With Increased Maternal Mortality in High-Risk Pregnancies Among South African Women
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 12, 2021

    Expires: March 11, 2022

  • DolPHIN-2 Final Results
    DolPHIN-2 Final Results: More Rapid Virologic Suppression With DTG- vs EFV-Based ART Started in Late Pregnancy Through 72 Wks Postpartum
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 10, 2021

    Expires: March 09, 2022

  • IMPAACT 2010 Update
    IMPAACT 2010 Update: Comparable Safety and Efficacy With DTG + FTC/TAF or FTC/TDF vs EFV/FTC/TDF at 50 Wks Postpartum Following Initiation in Pregnancy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 11, 2021

    Expires: March 10, 2022

  • ATLAS-2M Week 96 Results
    ATLAS-2M, Wk 96 Results: Long-Acting Injectable Cabotegravir + Rilpivirine Every 8 Wks Is Noninferior to Every 4 Wks
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 11, 2021

    Expires: March 10, 2022

  • REVAMP
    REVAMP: Management Guided by Genotypic Resistance Testing Following First-line ART Failure Comparable to Viral Load–Guided Management in Sub-Saharan Africa
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 08, 2021

    Expires: March 07, 2022

  • Vascular Events in PWH on ART
    Sex and Distinct Inflammation Pathways Predict Cardiovascular Disease and Vascular Events in Treated PWH
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 12, 2021

    Expires: March 11, 2022

  • Prévenir Update
    ANRS Prévenir: ANRS Prévenir: High Efficacy of Daily or On-Demand FTC/TDF PrEP Among Parisian MSM in Interim Analysis of Open-Label Prospective Cohort Study
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

Gilead

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare